News

On Thursday, the FDA granted full approval to Humacyte, Inc.’s (NASDAQ:HUMA) Symvess (acellular tissue-engineered vessel-tyod) use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss and when autologous vein graft is not feasible. Symvess, or the ATEV, is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for arterial replacement and repair. Also Read: Delay Hits Humac

On Friday, China’s central bank, the People’s Bank of China (PBOC), decided to maintain its main benchmark lending rates amid efforts to support economic growth while managing a weakening yuan. The one-year loan prime rate (LPR) remains at 3.1%, while the five-year LPR is steady at 3.6%, influencing corporate loans, household lending, and mortgages. This decision aligned with expectations from a Reuters poll of 27 economists, CNBC reports. Also Read: Amazon’s Project Kuiper In Talks With Taiwan

Slight upward revision to forecast comes in spite of mixed picture in regional markets.

The council expressed concerns about firms’ capacity to deliver high-quality audits, particularly as audit fees rise.

The benchmark US stock measures were tracking in the red before Friday's open as traders await the p

News of the day for Dec. 20, 2024

Using InvestCloud's APL platform, the PMA provides a centralised point for holding, and rebalancing alternative investments.